Introduction: Adults represent over half of incident T1D cases but most studies on risk prediction focus on children.

Methods: We studied 135,970 children (<18 years old) and 99,795 adult relatives in the TrialNet Pathway to Prevention study screened for autoantibody positivity (AB+). Kaplan Meier curves and log rank tests compare T1D progression. We tested discrimination of existing metabolic risk scores: Index60 (I60) and DPT1 (DPTRS) using area under time dependent receiver operating characteristic curve (ROC AUC).

Results: Adults had lower confirmed AB+ rates (adults 4.9% (n=4843); children 5.4% (n=7364), p < 0.001), particularly for multiple AB+ (adults 0.9% (n=939); children 3% (n=4062), p < 0.001). AB+ adults at all stages of disease exhibited lower 3 year progression risk compared to children (Table 1) but risk scores remained discriminative (DPTRS ROC AUC: adults 0.91 [0.87 - 0.94], children 0.86 [0.84 - 0.87]; I60: adults 0.87 [0.83 - 0.91], children 0.83 [0.82 - 0.85]).

Conclusion: Key differences and similarities between children and adult relatives are highlighted: fewer adults presented with early stage T1D (multiple AB+), progression rates were lower in AB+ adults, and those at highest risk can be identified with metabolic risk scores. Large datasets of AB+ adults are needed to refine and calibrate T1D prediction models in adults.

Disclosure

E. Templeman: None. L.A. Ferrat: Consultant; Johnson & Johnson Medical Devices Companies. N. Thomas: None. C. Speake: None. D.K. Wherrett: None. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. M.J. Redondo: None. C. Evans-Molina: Other Relationship; Bristol-Myers Squibb Company, Nimbus Therapeutics. Research Support; Lilly Diabetes, Astellas Pharma Inc. Advisory Panel; Avotres Inc., Neurodon, DiogenX, Isla Technologies. J. Sosenko: None. E.K. Sims: Consultant; Sanofi. Board Member; American Diabetes Association. Other Relationship; American Diabetes Association, Medscape. Consultant; DRI. R.A. Oram: Research Support; Randox R & D. Consultant; Provention Bio, Inc., Sanofi.

Funding

Randox Ltd

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.